Details of the Drug Combination

General Information of Drug Combination (ID: DCJ7ZSV)

Drug Combination Name
Amonafide Ixabepilone
Indication
Disease Entry Status REF
Astrocytoma Investigative [1]
Component Drugs Amonafide   DMAH59S Ixabepilone   DM2OZ3G
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: SNB-19
Zero Interaction Potency (ZIP) Score: 3.38
Bliss Independence Score: 5.9
Loewe Additivity Score: 4.1
LHighest Single Agent (HSA) Score: 5.84

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Amonafide
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Phase 3 [2]
Ovarian cancer 2C73 Phase 3 [2]
Prostate cancer 2C82.0 Phase 3 [2]
Indication(s) of Ixabepilone
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Approved [3]
Breast carcinoma N.A. Approved [4]
Ixabepilone Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Tubulin (TUB) TTML2WA NOUNIPROTAC Stablizer [5]
------------------------------------------------------------------------------------
Ixabepilone Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [6]
------------------------------------------------------------------------------------
Ixabepilone Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [7]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adenocarcinoma DCN2UHD DU-145 Investigative [1]
Adenocarcinoma DCI84K8 A549 Investigative [1]
Adenocarcinoma DC9MQQL HCT-15 Investigative [1]
Adult acute myeloid leukemia DCZ7ZGQ HL-60(TB) Investigative [1]
Adult T acute lymphoblastic leukemia DCK9R9T MOLT-4 Investigative [1]
Amelanotic melanoma DCCLHA8 M14 Investigative [1]
Astrocytoma DC8V8OK U251 Investigative [1]
Childhood T acute lymphoblastic leukemia DC6LHDX CCRF-CEM Investigative [1]
Glioma DCZRZ1C SF-295 Investigative [1]
Malignant melanoma DCY13QG UACC62 Investigative [1]
Malignant melanoma DCT1CR6 LOX IMVI Investigative [1]
Pleural epithelioid mesothelioma DCFEH7X NCI-H226 Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 12 DrugCom(s)

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 ClinicalTrials.gov (NCT00715637) Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDEStudy. U.S. National Institutes of Health.
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6824).
4 Ixabepilone FDA Label
5 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
6 Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 2011 May;337(2):423-32.
7 The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: a first in class epothilone B analogue in late-phase clinical development. Clin Cancer Res. 2008 May 1;14(9):2701-9.